Therapeutic Industry Analysis
Therapeutic Healthcare research reports cover strategic information on the following areas Women's Health, Vaccines, Obesity, CNS / Neurology and Oncology.
previous
| Competitor Analysis: Pseudomonas aeruginosa Vaccines and Therapeutics (LME00117) The present Competitive Intelligence Report about Pseudomonas aeruginosa Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, peptides and small molecules as well... | May 2012 | £250 |
| Deep Research Report on China Influenza Vaccine Industry (QYR00088) 20122012 Deep Research Report on China Influenza Vaccine Industry was a professional and depth research report on China Influenza Vaccine Industry. Firstly the report describes the background knowledge of Influenza... | May 2012 | £1,390 |
| Emergency Contraception in South Africa (EUR07059) South Africa remains one of the top countries in Africa where there is serious alcohol consumption amongst teenagers, this trend has led to a general increase in the number of... | May 2012 | £600 |
| Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics (LME00146) The present Competitive Intelligence Report about prophylaxis and therapy of S. aureus infections provides a competitor evaluation in the field of molecules for prevention or treatment of Staphylococcus aureus infections... | May 2012 | £250 |
| Analytical Tool - Protein Kinase Inhibitors in Oncology (BSK00044) "Analytical Tool - Protein Kinase Inhibitors in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in the drug development of protein kinase... | May 2012 | £3,670 |
| Therapeutic Drug Monitoring - Technologies, Markets, and Companies (JAI00045) This report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs... | May 2012 | £1,575 |
| Antiviral Therapeutics -Technologies, Markets and Companies (JAI00025) This report reviews the current state-of-art of antiviral approaches including vaccines, pharmaceuticals and innovative technologies for delivery of therapeutics. The introduction starts with a practical classification of viral diseases according... | May 2012 | £2,210 |
| Pain Therapeutics - Drugs, Markets and Companies (JAI00037) This report describes the latest concepts of pathomechanisms of pain as a basis for management and development of new pharmacotherapies for pain. Major segments of the pain market are arthritis,... | May 2012 | £2,525 |
| Neuroprotection - Technologies, Markets and Companies (JAI00035) This report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because... | May 2012 | £3,155 |
| Personalized Medicine - scientific & commercial aspects (JAI00038) The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a... | May 2012 | £3,155 |
| Competitive Insights to Protein Kinase Therapeutics in Oncology (BSK00564) The Faster Route to Consider Your Options and Position of OthersThis report represents a new and unique way of stratifying and analyzing the global protein kinase drug pipeline in oncology towards personalized medicine. It will excel your competitive awareness and... | May 2012 | £2,435 |
| Orphan Disease Therapeutics Market to 2018 (GBI00385) Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster InnovationOrphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation Summary GBI Research, the leading business intelligence provider, has released... | Apr 2012 | £2,210 |
| Orphan Diseases Therapeutics in Oncology to 2018 (GBI00390) Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage MoleculesOrphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules Summary GBI Research, the leading business intelligence provider,... | Apr 2012 | £2,210 |
| Autoimmune Disorders Therapeutics Market to 2017 (GBI00389) Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic SegmentsAutoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments Summary GBI Research, the leading business intelligence... | Apr 2012 | £2,210 |
| Cytotoxic Therapies Market to 2017 (GBI00387) Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic ErosionCytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion Summary GBI Research, the leading business intelligence provider, has released its... | Apr 2012 | £2,210 |
| Rheumatoid Arthritis Drugs Market in Japan (INF01628) 2011-2015TechNavio's analysts forecast the Rheumatoid Arthritis market in Japan to grow at a CAGR of 29.2 percent over the period 2011-2015. One of the key factors contributing to this market... | Apr 2012 | £945 |
| Emergency Contraception in France (EUR05702) Current value sales of emergency contraception grew by 9% in 2011. This growth was relatively similar to but slightly lower than the CAGR observed during the review period. Even if... | Apr 2012 | £600 |
| Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders (GDA29446) Summary GlobalData's report, 'Breaking the Gene Therapy Barrier for Life-Threatening Red Blood Cell Disorders' takes a look at gene therapy for the treatment of blood disorders such as beta-thalassemia and sickle... | Apr 2012 | £315 |
| Will Anyone Crack the Obesity Drug Market? (ESP00347) Following the FDA’s decision on Orexigen’s Contrave, the question is: Will a successful obesity drug market ever develop?Use this report to: Understand the state of play with Orexigen’s Contrave Review the... | Apr 2012 | £1,495 |
| Colorectal Cancer Drug Futures (ESP00727) Early-Stage Colorectal Cancer (Crc) Is Generally Treated with Surgery and Radiation.... ....with a high percentage of patients going on to survive disease free. Unfortunately, only around 40% of CRCs are found... | Apr 2012 | £1,495 |
| Breast Cancer Drug Futures (ESP00731) Globally, Breast Cancer Is The Second Most Common Cancer after Lung Cancer.... ....and the most common cancer for women. IT is the second most common cause of death from cancer... | Apr 2012 | £1,495 |
| Vaccines - United States (GRD03023) This market research report offers an in-depth perspective on the actual market situation, trends and future outlook for vaccines in United States. The analysis provides essential market information for decision-makers... | Apr 2012 | £405 |
| Vaccines - Uruguay (GRD03024) This market research report offers an in-depth perspective on the actual market situation, trends and future outlook for vaccines in Uruguay. The analysis provides essential market information for decision-makers including: Overall... | Apr 2012 | £405 |
| Vaccines - Global (GRD07970) This market research report package offers an in-depth perspective on the actual market situation, trends and future outlook for pasta in global markets. The analyses provide essential market information for... | Apr 2012 | £16,500 |
| Vaccines - Europe (GRD07971) This market research report package offers an in-depth perspective on the actual market situation, trends and future outlook for vaccines in European markets. The analyses provide essential market information for... | Apr 2012 | £9,320 |
